Rhumbline Advisers Has $1.48 Million Holdings in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)

Rhumbline Advisers raised its stake in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) by 6.5% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 120,810 shares of the company’s stock after acquiring an additional 7,361 shares during the quarter. Rhumbline Advisers’ holdings in Syndax Pharmaceuticals were worth $1,484,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Virtus ETF Advisers LLC increased its position in Syndax Pharmaceuticals by 18.6% in the 4th quarter. Virtus ETF Advisers LLC now owns 5,278 shares of the company’s stock valued at $70,000 after acquiring an additional 827 shares in the last quarter. Cape Investment Advisory Inc. increased its position in Syndax Pharmaceuticals by 157.1% in the 4th quarter. Cape Investment Advisory Inc. now owns 6,427 shares of the company’s stock valued at $85,000 after acquiring an additional 3,927 shares in the last quarter. Optimize Financial Inc acquired a new stake in Syndax Pharmaceuticals in the 4th quarter valued at about $152,000. Lazard Asset Management LLC acquired a new stake in Syndax Pharmaceuticals in the 4th quarter valued at about $153,000. Finally, Guggenheim Capital LLC acquired a new stake in Syndax Pharmaceuticals in the 4th quarter valued at about $157,000.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on SNDX shares. Scotiabank raised their target price on shares of Syndax Pharmaceuticals from $16.00 to $17.00 and gave the company a “sector perform” rating in a research note on Tuesday, May 6th. HC Wainwright reaffirmed a “buy” rating and issued a $51.00 target price on shares of Syndax Pharmaceuticals in a research note on Tuesday, March 4th. Guggenheim reaffirmed a “buy” rating and issued a $32.00 target price on shares of Syndax Pharmaceuticals in a research note on Tuesday, May 6th. Wall Street Zen raised shares of Syndax Pharmaceuticals to a “sell” rating in a research note on Tuesday, May 6th. Finally, Citigroup reduced their target price on shares of Syndax Pharmaceuticals from $45.00 to $42.00 and set a “buy” rating on the stock in a research note on Tuesday, March 4th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and ten have given a buy rating to the company. Based on data from MarketBeat, Syndax Pharmaceuticals has an average rating of “Moderate Buy” and a consensus target price of $35.91.

Syndax Pharmaceuticals Stock Up 0.5%

Syndax Pharmaceuticals stock opened at $9.69 on Thursday. The company’s 50 day simple moving average is $11.15 and its 200 day simple moving average is $12.94. Syndax Pharmaceuticals, Inc. has a fifty-two week low of $8.58 and a fifty-two week high of $25.07. The firm has a market capitalization of $833.82 million, a price-to-earnings ratio of -2.51 and a beta of 0.74. The company has a debt-to-equity ratio of 1.53, a current ratio of 5.80 and a quick ratio of 5.75.

Syndax Pharmaceuticals (NASDAQ:SNDX) last released its quarterly earnings data on Monday, May 5th. The company reported ($0.98) earnings per share for the quarter, topping the consensus estimate of ($1.04) by $0.06. Syndax Pharmaceuticals had a negative net margin of 757.53% and a negative return on equity of 101.60%. The business had revenue of $20.04 million for the quarter, compared to analyst estimates of $15.88 million. During the same quarter last year, the firm earned ($0.85) EPS. Syndax Pharmaceuticals’s quarterly revenue was up 1900.0% compared to the same quarter last year. As a group, sell-side analysts anticipate that Syndax Pharmaceuticals, Inc. will post -3.72 EPS for the current year.

Syndax Pharmaceuticals Company Profile

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).